March 29, 2008 (Sawf News) - Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
Collagenase-2 is a member of a protein family called matrix metalloproteinases (MMPs, collagenase-2 is MMP8), a large group of enzymes that break down collagen and other components of the body's connective tissue. MMPs have been implicated in contributing to MS by degrading the tissue that maintains the blood-brain barrier, thus allowing unwanted cells to invade and break down nerves.
People affected with the disease have been found to have elevated amounts of MMPs in their blood and spinal fluid.
Carlos Lopez-Otin and colleagues used a mouse model of MS and performed two analyses on MMP8 to determine the relevance of this protein to the disease.
First, they developed mutant mice deficient in the gene for MMP8 and found that these mice had a fewer invading cells in the brain, fewer damaged nerves, and a general improvement in their clinical profile.
Then they gave the diseased mice a drug that blocked MMP8 activity and found that this, too, could reduce the severity of disease symptoms.
Taken together, these promising findings provide the first causal evidence for MMP8 in the development of MS, and offer a new therapeutic target.
This study appears in the March 28 JBC online.
News Copyright © Sawf News. May not be reproduced without explicit written permission